# NRG-GI002 (NCT02921256)

> Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

No report yet. It can be ordered.

- Drugs tested: veliparib; pembrolizumab
- Indication: locally advanced rectal adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02921256
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Rectal Adenocarcinoma; Stage II Rectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7
- Interventions: Capecitabine; Fluorouracil; Intensity-Modulated Radiation Therapy; Leucovorin; Oxaliplatin; Pembrolizumab; Veliparib
- Enrollment: 363
- Primary outcome: Neoadjuvant Rectal Cancer (NAR) Score

## Indexed commentary on NRG-GI002 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 23
- Podcasts: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nrg-gi002-nct02921256

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02921256", "email": "<work email>"}; the inbox owner confirms by the emailed link.